Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ST3Gal1 is an inverting glycosyltransferase enzyme that catalyzes the transfer of sialic acid residues from the donor substrate CMP-Neu5Ac (CMP-N-acetylneuraminic acid) to acceptor substrates containing a terminal galactose residue[1]. The enzyme specifically recognizes the core 1 oligosaccharide motif Galβ1-3GalNAc found in Ser/Thr O-glycans of glycoproteins and ganglio-series glycolipids, forming α2,3 linkages[1][3]. ST3Gal1 belongs to the GT29 family of sialyltransferases and assumes a GT-A fold structure[3]. The enzyme operates through a direct displacement SN2-like mechanism, with histidine residues H299 and H316 acting as acid and base catalysts respectively[1]. Key residues including Y191, Y230, N147, S148, N170, and Y266 contribute to donor and acceptor substrate binding through hydrogen bonds and stacking interactions[1]. The catalytic site contains conserved motifs including the HP (His-Pro) motif and maintains activity through proper formation of disulfide bonds[1][3]. Overexpression of ST3Gal1 leads to hypersialylation of cell-surface glycoconjugates, a cancer-associated condition that promotes cell growth, migration, and invasion[1]. In ovarian cancer, upregulation of this enzyme is specifically linked to cancer progression, metastasis, and contributes to chemotherapy resistance[1][5]. The enzyme shows strict regioselectivity and substrate preference, with an optimal pH between 6 and 6.5, and does not require metal ions for activity[3]. ST3Gal1 preferentially acts on acceptors with the Galβ1-3GalNAc structure in both core 1 and core 2 O-glycans, with apparent Km values in the range of 0.05-0.2 mM for various acceptor substrates[3].
Catalytic inhibition to prevent hypersialylation; Blockade of sialic acid transfer to reduce cancer cell metastasis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CMP-N-acetylneuraminate-beta-galactosyl-1,3-N-acetylgalactosaminide alpha-2,3-sialyltransferase 1 (ST3GAL1) (ST3Gal1 or ST3Gal-I).